Consumer Healthcare update Financial performance Outlook 2024 Appendices Q4 2023 Booster vaccines 22 Vaccines performance Polio/ Pertussis/Hib €434m +3.4% Influenza €741m -4.0% €20m -76.1% Meningitis and PPH franchises benefited from public order pattern in the quarter Specialty Care Vaccines GenMed RSV Toddler for 2nd season onwards Innovative vaccines for all target populations • Phase 3 start in Q1 2024 PCV (Prevnar) and Rotavirus (Rotateq) data from IQVIA DDD for private doses, and CDC data for public d ...

Sanofi (NASDAQ:SNY) JPMorgan 42nd Annual Healthcare Conference Call January 9, 2024 1:30 PM ET Company Participants Paul Hudson - Chief Executive Officer Jean-Baptiste de Chatillon - Executive Vice President and Chief Financial Officer Houman Ashrafian - Executive Vice President and Head of Research and Development Conference Call Participants Richard Vosser - JPMorgan Richard Vosser Hi, welcome to the Sanofi Presentation at the 42nd JPMorgan Healthcare Conference. I'm Richard Vosser, European Pharma Analys ...

This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding ...

Jean-Baptiste de Chatillon Julie, on switches. . Yes. I think that there's still a great path forward for perhaps Cialis, we're a bit more -- can be more transparent about because we can see it clearly after the latest conversations and the market opportunity for both is significant. So as and when we get the updates for share, but I think also they're very important value credit moments in the future of CHC. So I think perhaps that's why you asked it, but that's still very real. . Two, if I may, would revi ...

Press Release Specialty Care growth, strong launch uptake of Beyfortus and ALTUVIIIO drive solid Q3 results ® ® Paris, October 27, 2023 Q3 2023 sales growth of 3.2% at CER and business EPS decrease of 2.1% at CER (1) Key R&D milestones and regulatory achievements in Q3 Progress on Corporate Social Responsibility strategy in Q3 • Sanofi Global Health Unit: first deliveries of cardio-metabolic products under the Impact brand to the Republic of Djibouti and to global non-governmental organizations Full-year 20 ...

Jo Walton Apologies for that. I just have two questions, please. I noticed that Dietmar isn't on the Executive Committee just looking at the -- on your website. I wonder if you could tell us when you're going to be in a position to announce the head -- a new permanent head of R&D? And could I just ask related, another R&D-related question. It's a couple of years now since you bought Title IP for the targeted delivery CAR-T, certain cell types? I wonder -- this area still looks to be facing real challenges. ...

Phase II As of June 30, 2023. For collaborations see slide 59. For abbreviations see slide 60. 1. Also known as SAR445229. 2. Also known as SAR443122/DNL758. 3. Also known as SAR441344. 4. Also known as SAR445256. 5. Also known as DNL788. 6. Also known as SP0178. R&D Pipeline – Phase I As of June 30, 2022. For collaborations see slide 59. For abbreviations see slide 60. 1. Also known as KT474. Planned to start Ph2 studies in HS and AD. 3. Also known as KD033. 4. Also known as KD050. 5. Also known as AMX-818 ...

Exhibit 99.1 | | TABLE OF CONTENTS | | | --- | --- | --- | | 1. | CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS | 2 | | | CONSOLIDATED BALANCE SHEETS – ASSETS | 2 | | | CONSOLIDATED BALANCE SHEETS — SHAREHOLDERS' EQUITY AND LIABILITIES | 3 | | | CONSOLIDATED INCOME STATEMENTS | 4 | | | CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | 5 | | | CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY | 6 | | | CONSOLIDATED STATEMENTS OF CASH FLOWS | 8 | | | NOTES TO THE CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL ...

Sanofi (NASDAQ:SNY) Goldman Sachs 44th Annual Global Healthcare Conference Call June 14, 2023 1:00 PM ET Company Participants Bill Sibold - Executive Vice President Specialty Care; President, Sanofi North America Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Welcome to our continued morning here at the Third Day of the Goldman Sachs Healthcare Conference. My name is Chris Shibutani, member of the research team on the global front, along with many strong associates across the b ...

And just 2 quick ones. Firstly, just on the oral TNF again. Obviously, one of the indications where we are seeing OTNF still be used and actually not facing the same competition is HS, where I think you've also got some other programs looking at as well. I'm curious, I guess, why necessarily the focus on psoriasis, which is a pretty competitive market and I guess not some other potential statements as there are where perhaps less competition about the more amenable there for you to be an early entrant. Thom ...